XenTech is a Patient-Derived Tumor Xenograft platform

Offering preclinical cancer models and services for translational drug development

To foster therapeutic development in oncology, XenTech performs preclinical pharmacology studies using one of the world's largest and best characterized collection of patient-derived tumor xenograft models (PDX) established without intermediary cell culture.

Database access

Search your model into our PDX library

Login :

Password :

> Create an account

Latest news

March 20-22nd, 2017 | Barcelona, Spain | Bio Europe Spring

XenTech is pleased to attend to the 11th BIO Europe Spring event on March in Barcelona. It is the perfect occasion to meet you and talk about your projects in preclinical development of anti cancer drugs. More info about this partnering conference here. To set up a meeting with our dedicated team, send us a […]

Company

Contract Research Organization

XenTech is primarily a contract research organization (CRO) specializing in preclinical evaluation of novel anti-tumor agents. The company also conducts internal R&D programs....

Partnerships

Research collaborations

XenTech has several research collaborations with pharmaceutical and biotechnology companies and with academic institutions. XenTech has established key collaborations with clinical centers in France...